AN2 Therapeutics (ANTX) vs Bicycle Therapeutics (BCYC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
AN2 Therapeutics (ANTX) has outperformed Bicycle Therapeutics (BCYC) over the past year, gaining 366.1% versus a loss of 54.1%. Bicycle Therapeutics is the larger company by market cap ($203.3 million vs $192.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANTX | BCYC |
|---|---|---|
| Share price | $5.08 | $2.90 |
| Market cap | $192.75M | $203.27M |
| 1-day change | -2.68% | -4.92% |
| YTD return | +345.61% | -59.04% |
| 1-year return | +366.06% | -54.11% |
| 5-year return | — | -94.69% |
| EPS (TTM) | $-0.91 | $-2.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $72.59M |
| Revenue growth (YoY) | — | +105.77% |
| Net income (latest FY) | $-35.17M | $-218.96M |
| Operating margin | — | -340.38% |
| Net margin | — | -301.66% |
| 52-week high | $7.19 | $7.83 |
| 52-week low | $1.00 | $2.85 |
| Distance from 52-week high | -29.35% | -62.96% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +77.17% | +216.21% |
| Average volume | 289.29K | 444.72K |
| Shares outstanding | 37.94M | 50.66M |
| Employees | 21 | 288 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANTX has outperformed BCYC by 420.2 percentage points over the past year.
About AN2 Therapeutics
ANTX stock →AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Bicycle Therapeutics
BCYC stock →Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
Health Care · Biotechnology: Pharmaceutical Preparations · 288 employees
ANTX vs BCYC FAQ
Which is bigger, AN2 Therapeutics or Bicycle Therapeutics?
Bicycle Therapeutics (BCYC) is larger, with a market capitalization of $203.27M compared with $192.75M for AN2 Therapeutics (ANTX).
Which stock has performed better over the past year, ANTX or BCYC?
ANTX returned +366.06% over the past 12 months, compared with -54.11% for BCYC (price return, excluding dividends). Past performance does not predict future results.
Are AN2 Therapeutics and Bicycle Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.